Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement
Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.
Efficacy of Rituximab Retreatment in Refractory Systemic Juvenile Idiopathic Arthritis.
Alexeeva, Ekaterina, Valieva, Saniya, Bzarova, Tatyana, Denisova, Rina, Isayeva, Kseniya, Sleptsova, Tatyana, Mitenko, Elena
Chimeric monoclonal anti-CD20 B-cell antibody (rituximab) is promising drug for the treatment of JIA refractory to immunosuppressive drugs and TNF-a-blockers. To evaluate clinical efficacy of rituximab retreatment in patients with severe systemic juvenile idiopathic arthritis (JIA).
75 patients were enrolled in the study, 36 boys and 39 girs with JIA. Range of age was from 2,3 to 17 years; mean disease duration was 5,32 (0.6; 7,0) years. Rituximab was administered at a mean dose of 375 mg/m2/administration according to the following regimen: 1 dose once a week for 4 consecutive weeks every 24 weeks. The next course of Rituximab was administrated if patients had systemic manifestations, active joints, increasing level of CRP and ESR in 24 weeks after Rituximab treatment. 75 patients have received one treatment course (24 weeks), 72 children have received 2 courses (48 weeks), 55 children have received 3 courses (72 weeks), 384 courses (96 weeks), 235 courses (120 weeks)
The number of systemic manifestations was significantly reduced from 4,5±1,3 to 2,8±1,4, 1,6±0,9, 0,5±0,4, 0,7±0,5 and 0,5±0,3 at Week 24, 48, 72, 96 and 120, respectively. The ACR Pedi 30, 50, 70 were achieved by 85%,45%, 40% of patients at Week 24, and by 90%, 75%, 70% of patients at Week 48, respectively. At week 72 ACR pedi 50 and 70 were achieved by 75% and 70% of patients. The remission was achieved by 25% of patients at Week 24, by 48% of patients at Week 48, by 65% of patients at Week 72 and by 80% and 90% of patients at Week 96 and 120.
Rituximab is effective drug of treatment in patients with severe juvenile idiopathic arthritis. The remission was achieved by 90% of patients at Week 120.
To cite this abstract, please use the following information:
Alexeeva, Ekaterina, Valieva, Saniya, Bzarova, Tatyana, Denisova, Rina, Isayeva, Kseniya, Sleptsova, Tatyana, et al; Efficacy of Rituximab Retreatment in Refractory Systemic Juvenile Idiopathic Arthritis. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :2626